MSI testing in appendix cancer is something most patients never hear about, and there is a reason for that. A positive result is rare. It comes back as MSI-high or mismatch repair deficient in only about 3 percent of cases. But that small group matters a great deal, and ruling it out is still worth doing.
Here is what the test is, how often it turns up positive, and why the answer is worth knowing even when it is likely to be negative.
What MSI and dMMR actually mean
Your cells have a built-in spell-check system that fixes small mistakes when DNA copies itself. The genes that run that system are called mismatch repair genes. When they work, the tumor is microsatellite stable, often written as MSS. When they stop working, mistakes pile up in short repeated stretches of DNA called microsatellites. A tumor like that is called microsatellite instability-high, or MSI-high, and the underlying breakdown is called mismatch repair deficient, or dMMR.
MSI-high and dMMR are two ways of describing the same biology. One is measured by looking at the DNA repeats directly. The other is measured by checking whether the repair proteins are present. A pathologist can run either test on tumor tissue you already have.
How often MSI testing in appendix cancer comes back positive
This is where appendix cancer is different from its better-known neighbor. In colorectal cancer, MSI-high shows up in roughly 15 percent of tumors, which is why testing is routine there. In appendiceal adenocarcinoma, the rate is far lower, only about 3 percent.
So if your tumor comes back microsatellite stable, you are in the large majority. That is the biology of this disease, not a failure of your care or a sign anything was missed.
Why MSI testing in appendix cancer is still worth doing
Two reasons, and both are big for the people they apply to.
First, treatment. If a tumor is dMMR or MSI-high, it can qualify for an immunotherapy called a checkpoint inhibitor. This is not a clinical trial. The FDA approved pembrolizumab for any dMMR or MSI-high solid tumor regardless of where it started, so a positive result can open a door to an already-approved drug without waiting for a trial slot.
Second, family. A dMMR or MSI-high result can be a clue to Lynch syndrome, an inherited condition that raises the risk of several cancers. Knowing that is worth it for your whole family, because it changes what screening your relatives should have and when. If that comes up, our post on appendix cancer genetic testing walks through what germline testing adds and why it can matter for the people you love.
The honest part
For most people with appendix cancer, especially low grade or mucinous disease, the tumor will be microsatellite stable and immunotherapy is not the answer. That is not bad news about your care. It is just what the biology of this disease usually looks like. MSI testing in appendix cancer is worth doing precisely because it tells you, one way or the other, whether you are in that rare group with another option on the table.
What to ask your care team
You do not need to memorize the science. One question covers it. Ask: has my tumor been tested for MMR or MSI, and if so, what did it show? If MSI testing in appendix cancer has not been done on your tumor, ask whether it can be, since the test usually runs on tissue you have already given.
If you want to help the wider community see how often appendix cancer is dMMR or MSI-high, and who it affects, adding your own diagnosis and testing details to our patient data registry is one of the most useful things you can do in ten minutes.
Sources
High-level microsatellite instability in appendiceal carcinomas. MD Anderson. pubmed.ncbi.nlm.nih.gov/23648460
Prognostic impact of microsatellite instability on appendiceal adenocarcinoma. National Cancer Database analysis. pubmed.ncbi.nlm.nih.gov/36650414
Hashimoto et al. Appendiceal goblet cell adenocarcinoma with dMMR and MSI-high status. Pathology International, 2026. onlinelibrary.wiley.com/doi/10.1111/pin.70108
This post is patient education from Appendicure and is not medical advice. Testing and treatment decisions should be made with your own care team.
Leave a Reply